| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2015-06-11 | Cosentyx® - secukinumab (AIN457) | palmoplantar psoriasis | 3 | Novartis (Switzerland) | Autoimmune diseases - Dermatological diseases |
| 2015-06-11 | ImmuKnow® test | solid organ transplantation | Eurofins Scientific (Luxembourg) | Transplantation | |
| 2015-06-10 | MK-8237 (House Dust Mite Sublingual Allergen Immunotherapy Tablet) | house dust mite-induced allergic rhinitis | 2b | Merck&Co (USA) ALK Abello (Denmark) | Allergic diseases - Immunological diseases |
| 2015-06-10 | Cosentyx® (secukinumab) (AIN457) | ankylosing spondylitis | 3 | Novartis (Switzerland) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2015-06-10 | Inflectra™/Remsima™ (infliximab) | inflammatory conditions including rheumatoid arthritis, ankylosing spondylitis, Crohn\'s disease, ulcerative colitis, psoriatic arthritis, psoriasis, rheumatoid arthritis | post-marketing | Hospira (USA - IL) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2015-06-10 | veliparib (ABT-888) | ovarian cancer | 3 | Abbvie (USA - IL) | Cancer - Oncology |
| 2015-06-10 | ixekizumab | moderate-to-severe plaque psoriasis | 3 | Eli Lilly (USA - IN) | Autoimmune diseases - Dermatological diseases |
| 2015-06-10 | SB4 - Enbrel® (etanercept) biosimilar candidate | moderate to severe rheumatoid arthritis |
3 | Merck&Co (USA - NJ) Samsung Biologics (Republic of Korea) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2015-06-10 | SB2 - Remicade® (Infliximab) biosimilar candidate | moderate to severe rheumatoid arthritis |
3 | Merck&Co (USA - NJ) Samsung Biologics (Republic of Korea) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2015-06-10 | XmAb®5871 | rheumatoid arthritis |
1b/2a | Xencor (USA - CA) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2015-06-10 | allogeneic CAR T-cells | Cellectis (France) | Cancer - Oncology | ||
| 2015-06-09 | NBTXR3 | head and neck cancer | 1-2 | Nanobiotix (France) | Cancer - Oncology |
| 2015-06-09 | LentiGlobin® BB305 (autologous CD34+ haematopoietic stem cells transduced with lentiviral vector encoding the human beta A-T87Q-globin gene) | beta-thalassemia major | 1 | Bluebird bio (USA - MA) | Genetic diseases - Hematological diseases - Rare diseases |
| 2015-06-09 | Aristada® (aripiprazole lauroxil - ALKS 9070) | schizophrenia | 3 | Alkermes (Ireland) | CNS diseases - Mental diseases |
| 2015-06-09 | Otezla® (apremilast) | psoriatic arthritis | 3 | Celgene (USA - NJ) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2015-06-08 | Toujeo® (insulin glargine (rDNA origin) injection 300 U/mL) | diabetes |
3 | Sanofi (France) | Metabolic diseases |
| 2015-06-08 | Trulicity™ (dulaglutide) | type 2 diabetes |
3 | Eli Lilly (USA - IN) | Metabolic diseases |
| 2015-06-08 | AB101 | diabetes |
preclinical | AntriaBio (USA - CO) | Metabolic diseases |
| 2015-06-08 | efpeglenatide | type 2 diabetes
|
2 | Hanmi Pharmaceutical (South Korea) | Metabolic diseases |
| 2015-06-08 | Lyxumia® (lixisenatide) | type 2 diabetes |
3b | Sanofi (France) | Metabolic diseases |
